Non-Small Cell Lung Cancer (NSCLC) Clinical Trials

• Age ≥ 18 years old at the time of enrollment

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1

• Expected life expectancy ≥ 3 months

• Metastatic (Stage IV) NSCLC

• Histologically or cytologically confirmed squamous or non-squamous NSCLC

• Tumor demonstrates high PD-L1 expression ( TPS\>50%) based on a 22C3 immunohistochemistry ( IHC) clinical assay approved / cleared by local health authorities.

• At least one measurable noncerebral lesion according to RECIST 1.1

• No prior systemic treatment for metastatic NSCLC.